These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 11389123

  • 1. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ, Giles C, Turnidge JD.
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [Abstract] [Full Text] [Related]

  • 2. The post-antibiotic effects of linezolid against Gram-positive pathogens.
    Hosgor-Limoncu M, Ermertcan S, Tasli H, Aydemir S.
    Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
    [Abstract] [Full Text] [Related]

  • 3. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT, Zurenko GE.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [Abstract] [Full Text] [Related]

  • 4. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
    Stefani S, Mezzatesta ML, Tempera G, Debbra E, Schito AM, Nicoletti G, Marchére A.
    Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
    Johnson AP, Warner M, Livermore DM.
    J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 7. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.
    Bell JM, Turnidge JD, Ballow CH, Jones RN, ZAPS Regional Participants.
    J Antimicrob Chemother; 2003 Feb; 51(2):339-45. PubMed ID: 12562700
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility testing of linezolid by two standard methods.
    Hamilton-Miller JM, Shah S.
    Eur J Clin Microbiol Infect Dis; 1999 Mar; 18(3):225-7. PubMed ID: 10357061
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [Abstract] [Full Text] [Related]

  • 11. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
    Ho PL, Ng TK, Yung RW, Que TL, Yip EK, Tse CW, Yuen KY.
    J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
    [No Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S, Chatzidimitriou M, Nikolaidis P, Tsona A, Bisiklis A, Kollaras P, Tsiakiri E, Koumentaki E, Alexiou-Daniel S.
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM, Warner M, Mushtaq S, North S, Woodford N.
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [Abstract] [Full Text] [Related]

  • 14. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
    Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A.
    J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
    [Abstract] [Full Text] [Related]

  • 15. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN, Fritsche TR, Sader HS, Ross JE.
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections.
    Onda H, Wagenlehner FM, Lehn N, Naber KG.
    Int J Antimicrob Agents; 2001 Sep; 18(3):263-6. PubMed ID: 11673040
    [Abstract] [Full Text] [Related]

  • 17. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
    Johnson AP, Warner M, Livermore DM.
    J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM, Thorne GM, Luperchio SA, Alder JD.
    Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Nov; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 20. Action of linezolid or vancomycin on biofilms in ventriculoperitoneal shunts in vitro.
    Bayston R, Ullas G, Ashraf W.
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2842-5. PubMed ID: 22430965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.